| Autor: |
Yoshihiko Yano, Atsushi Yamamoto, Akihiro Minami, Kenji Momose, Takuya Mimura, Soo Ki Kim, Hiroki Hayashi, Takuo Kado, Hirotaka Hirano, Seiya Hirohata, Seitetsu Yoon, Katsuhisa Nishi, Hiroshi Tei, Hidenori Tanaka, Sachiko Oouchi, Takanori Matsuura, Eiichiro Yasutomi, Yuri Hatazawa, Yuuki Shiomi, Yoshihide Ueda, Yuzo Kodama |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
JGH Open, Vol 6, Iss 6, Pp 427-433 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2397-9070 |
| DOI: |
10.1002/jgh3.12772 |
| Popis: |
Abstract Background and Aim Molecular‐targeted therapies such as sorafenib and lenvatinib have long been used as first‐line treatment for advanced hepatocellular carcinoma (aHCC). However, adverse events or limited therapeutic effects may necessitate the change to another therapeutic option, known as post‐progression therapy. To investigate the significance of post‐progression therapy, we analyzed the outcomes of aHCC patients following first‐line molecular‐targeted therapy in a real‐world study. Methods This retrospective, multicenter study involved patients with aHCC who received sorafenib or lenvatinib as first‐line therapy between January 2011 and September 2021. Results In total, 513 patients were analyzed: 309 treated with sorafenib and 204 with lenvatinib. The overall response and disease control rates were 15 and 50%, respectively, in the sorafenib group and 30 and 75%, respectively, in the lenvatinib group (P |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Plný text